Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations

Intravitreal drug delivery is essential for multiple ocular diseases. Development of intravitreal formulations requires high-quality in vivo experiments that require a large number of animals. This development can be expedited by improving in vitro testing and utilizing in vitro - in vivo correlation. We propose an in vitro approach using vitreous in a dialysis membrane to conduct these studies. The model was developed for small molecules and evaluated with drugs in solution (13 drugs in one cassette and 4 in another), and a drug suspension. For solutions, 6 out of 8 drug compounds were within 2.5-fold difference to their experimental vitreal clearances. Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route.

Authors

Institutions

Publication Details

Journal
Journal of Controlled Release
Published
2025-05-06
DOI
https://doi.org/10.1016/j.jconrel.2025.113823
Citations
2
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
3.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations

Amir Sadeghi, Jarmo T. Laitinen, Iuliia Pilipenko, Eva M. del Amo et al.
2 citations
Journal of Controlled Release
Retinal Diseases and Treatments
3.41
article

Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations

Amir Sadeghi, Jarmo T. Laitinen, Iuliia Pilipenko, Eva M. del Amo, Timo Sorsa, Arto Urtti, Astrid Subrizi
article en
2 citations

Abstract

Intravitreal drug delivery is essential for multiple ocular diseases. Development of intravitreal formulations requires high-quality in vivo experiments that require a large number of animals. This development can be expedited by improving in vitro testing and utilizing in vitro - in vivo correlation. We propose an in vitro approach using vitreous in a dialysis membrane to conduct these studies. The model was developed for small molecules and evaluated with drugs in solution (13 drugs in one cassette and 4 in another), and a drug suspension. For solutions, 6 out of 8 drug compounds were within 2.5-fold difference to their experimental vitreal clearances. Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route.

Journal of Controlled ReleaseVol. 383
University of Eastern Finland (FI)
Zero hunger
Openalex Percentile: Top 9%
Retinal Diseases and Treatments
3.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.